Aequitas: Akeso Inc Placement Past Deals Have Been Weak but Current Raise Is Less Opportunistic
Akeso is looking to raise around US$250m in a primary offering. In this note, we talk about the deal dynamics and run the deal through our ECM...
69 Views
Akeso 9926.HK: 1H26 Results Missed on Topline; Upcoming Events on Harmoni-3 Readout and FDA PDUFA
Akeso 1H26 missed on topline. See inside for our thought on Akeso share price underperformance, upcoming catalysts on ivonescimab, 1H26 results...
109 Views
China Healthcare Weekly Wrap (28 Sep - 2 Oct)
Strong deal flows this week: 1) Abogen/Novartis on in vivo mRNA TCE; 2) Scibrunch/Merck on Kras G12D, 3) Hengrui/Novo on weekly oral GLP-1/GIP;...
94 Views
Akeso (9926.HK): SMMT 2Q26 Call Takeaways on Ivonescimab
SMMT: FPS data for Harmoni sq in late 2026; interim OS data in 1H27 being a crucial focus. Harmoni-3 update shows consistent HR 0.76 for Asian vs...
135 Views
Technically Speaking Breakouts & Breakdowns - HONG KONG (August 2026)
Genscript shares gain after the company announced it will provide wet-lab services to companies participating in Eli Lilly's TundeLab, helping them...
118 Views